Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer.
10.1097/CM9.0000000000001120
- Author:
Wen-Qian LI
1
;
Ling-Yu LI
;
Ri-Lan BAI
;
Lei QIAN
;
Nai-Fei CHEN
;
Jiu-Wei CUI
Author Information
1. Department of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
B7-H1 Antigen/genetics*;
Carcinoma, Non-Small-Cell Lung/genetics*;
Cost-Benefit Analysis;
Humans;
Immune Checkpoint Inhibitors;
Immunotherapy;
Ligands;
Lung Neoplasms/genetics*
- From:
Chinese Medical Journal
2020;133(21):2630-2632
- CountryChina
- Language:English
